The ELAINE trials and the future of personalized therapy for hormone-receptor positive metastatic breast cancer
Ann Oncol
.
2023 Dec;34(12):1071-1073.
doi: 10.1016/j.annonc.2023.10.792.
Author
Seth A Wander
1
Affiliation
1
Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Yawkey 9A, Boston, MA 02114. Electronic address: swander@mgh.harvard.edu.
PMID:
38072508
DOI:
10.1016/j.annonc.2023.10.792
No abstract available
Publication types
Editorial
Comment
MeSH terms
Antineoplastic Combined Chemotherapy Protocols
Breast Neoplasms* / drug therapy
Breast Neoplasms* / pathology
Female
Forecasting
Hormones / therapeutic use
Humans
Receptor, ErbB-2
Substances
Hormones
Receptor, ErbB-2